Skip to Content
Søk Menu

ESMO I European Society for Medical Oncology

ESMO 2025

Improved PFS and OS in HER2-Positive and Triple-Negative Breast Cancer

  • / Hanne Melgaard Nielsen / Jan Andreasen

T-DXd in Patients with High-Risk HER2-Positive Early Breast Cancer – Are We Ready to Change Practice?

/ Henrik Lindman / Jan Andreasen
ESMO25

DESTINY-Breast11 and Neoadjuvant T-DXd: Insights from Finland

/ Maria Sundvall / Jan Andreasen
BröstcancerESMO25NBCN

Emerging Treatment for High-Risk HER2-Positive Early Breast Cancer — A new therapeutic option for the primary refractory patients 

/ Jan Andreasen
BröstcancerESMO25
Load more

Significant therapeutic advancement for patients with HER2-positive biliary tract cancer

  • / Jan Andreasen

Artiklar till ESMO 2025

Sustained efficacy and quality of life with darolutamide + ADT in mHSPC patients of all ages

/ Jan Andreasen
ESMO25Prostatacancer

RNA Expression Profiles May Guide Future Targeted Therapy in Urothelial Cancer

/ Jan Andreasen
BlåscancerESMO25

Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study

/ Igle Jan de Jong / Jan Andreasen
ESMO25
Load more

Medtalks till ESMO 2025

Teresa Macarulla

ESMO 2025: HER2-Targeted Therapy Advances in BTC

/ Teresa Macarulla
ESMO25NBCN Play the Video
Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lungcancer Play the Video
John Crown

ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

/ John Crown
BröstcancerESMO25NBCN Play the Video
Load more

ESMO 2024

PD-1 Inhibitors Have Shown Remarkable Efficacy

  • / BestPractice Nordic

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ BestPractice Nordic
ESMO24Mag-tarmcancer

Several Unsettled Questions About Breast Cancer Treatment

/ BestPractice Nordic
BröstcancerESMO24

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ BestPractice Nordic
ESMO24Gynekologisk cancer
Load more

ESMO 2024

Kristina Lindemann

ESMO 2023 Highlights: Practice-Changing Research in Gynecologic Cancers

/ Kristina Lindemann
ESMO23Gynekologisk cancerPatientmedverkan Play the Video

Two New Potential Game-Changers in the Treatment of Gastroesophageal Cancer

/ Lene Bæksgaard
ESMO23Mag-tarmcancer Play the Video
Kristina Lindemann

Potential New Standard of Care for Locally Advanced Cervical Cancer

/ Kristina Lindemann
ESMO23Gynekologisk cancer Play the Video

Optimizing PARP Inhibitor Therapy for Ovarian Cancer

/ Onkologi / Mansoor Raza Mirza

Enabling Patient Empowerment Through Digital Monitoring

/ Onkologi / Ellinor Christin Haukland

ESMO 2023 Highlights: Developments in Melanoma

/ Onkologi / Marco Donia

Perioperative Pembrolizumab Shows Significant OS in ResectableNon-Small-Cell Lung Cancer

/ Onkologi / Jonathan Spicer

Prostate Cancer: Adaptive, Biomarker-Driven Platform Trial Shows That New Hormonal Agents Have Better Efficacy for mCRPC

/ Onkologi / Henrik Grönberg

Meet the experts • ESMO 2023

Få tillgang

Selected ESMO 2023 Highlights: Endometrial Cancer Treatment

/ Shannon Westin
ESMO23Gynekologisk cancer Play the Video
Mansoor Raza Mirza

New Treatment Possibilities for Patients with Recurrent or Primary Advanced Endometrial Cancer

/ Mansoor Raza Mirza
ESMO23Gynekologisk cancer Play the Video
Shannon Westin

Insights on Duo-E Trial: Advancing Endometrial Cancer Treatment with Olaparib

/ Shannon Westin
ESMO23Gynekologisk cancer Play the Video
Jaffer Ajani

Findings from the SPOTLIGHT Study Demonstrate the Power of the New Biomarker Claudin-18.2.

/ Jaffer Ajani
ESMO23Mag-tarmcancer Play the Video
Peter Schmid

Pembrolizumab + Chemotherapy: a New Standard of Carefor Triple-Negative Breast Cancer

/ Peter Schmid
BröstcancerESMO23 Play the Video
Arlene Siefker-Radtke

Urothelial Cancer: One Step Forward to Understand How to Combine and Sequence Treatments Against Novel Targets

/ Arlene O. Siefker-Radtke
ESMO23 Play the Video
Thomas Powles

Keynote A39: Enfortumab Vedotin + Pembrolizumab agroundbreaking First Line Treatment in Untreated la/mUC

/ Thomas Powles
BlåscancerESMO23 Play the Video

Maybe a Breakthrough for Patients with Untreated Locally Advanced Metastatic Urothelial Carcinoma 

/ BestPractice Nordic
ESMO23
Magnus Nilsson

Esophaguscancer: Aktiv övervakning vs. Neoadjuvant Kemoradioterapi följt av Kirurgi

/ Magnus Nilsson
ESMO23Mag-tarmcancer Play the Video
Fred Saad

Triplet Therapy with Darolutamide (DARO), Androgen-Deprivation Therapy (ADT) and Docetaxel (DOC) is a Game Changer in the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

/ Fred Saad
ESMO23Prostatacancer Play the Video
BestPractice Nordic

What We Expect at ESMO 2023

/ BestPractice Nordic
ESMO23 Play the Video
Back to top